Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The real concerns should be....

oh boy.

Alliacense is a TPL entity.

TPL has funding issues.

If the owners of TPL don't want to fund TPL, why should PTSC?

Why would PTSC make a second loan to TPL that is unseccured, when the first loan to TPL was secured? (PTSC won't give me an answer; maybe you and milestone can text in for one)

Did accounting principles call for a compulsory and complete writedown to zero, or does PTSC internally value the loan at zero, if so why?

The rest of your 'lecture' is not worth commenting on.

Share
New Message
Please login to post a reply